Regulatory updates, clinical trial results, and research developments in the peptide space — curated for patients, researchers, and healthcare professionals.
A major 2025 review in Frontiers in Nutrition synthesizes over 60 clinical studies on oral collagen peptide supplementation, finding meaningful effects on skin elasticity, joint function, and exercise recovery — particularly with the right co-supplements.
PubMed PMID:41459089
Researchers have engineered a tandem thymosin beta-4 peptide that outperforms the native molecule for corneal wound healing in preclinical studies, with implications for how next-generation regenerative peptides might be developed.
PubMed PMID:41235866
A randomized, placebo-controlled trial published in EBioMedicine demonstrates that intranasal kisspeptin-54 rapidly stimulates gonadotropin release in healthy adults and patients with hypothalamic amenorrhoea — offering the first non-invasive method to reactivate the reproductive hormone axis.
PubMed PMID:40215751
As GLP-1 receptor agonists transform obesity treatment, a 2026 review in the Journal of Clinical Medicine examines the muscle loss problem they create — and the peptide therapies being developed to address it, including tesamorelin.
PubMed PMID:41598480
A critical review published in March 2026 examines the growing use of growth hormone secretagogues and other peptides in both elite sport and recreational fitness — and finds the risk profile is more concerning than the marketing suggests.
PubMed PMID:41880199
A randomized controlled trial published in April 2026 finds that thymosin α1, an immune-modulating peptide, significantly improved 90-day transplant-free survival in patients with hepatitis B virus-related acute-on-chronic liver failure.
PubMed PMID:41887933
A comprehensive review in the International Journal of Molecular Sciences examines preclinical evidence for BPC-157's reparative and analgesic properties — and outlines what still needs to happen before it could be recommended clinically.
PubMed PMID:41898733
A landmark Nature study of nearly 28,000 patients identifies genetic variants in the GLP1R and GIPR genes that predict both weight loss response and nausea risk from semaglutide and tirzepatide.
PubMed PMID:41951734
A new review in Obesity Science & Practice examines the gut-brain axis and makes the case for combining GLP-1 receptor agonists with naltrexone/bupropion to address multiple pathways in obesity treatment.
PubMed PMID:41947825
BPC-157 remains under FDA review as a Category 2 bulk substance for compounding. Here is what the current status means for patients and consumers seeking this peptide.
Informed Peptide Editorial
New clinical data published in 2025 and early 2026 is reshaping how physicians and patients understand the long-term effects of semaglutide and tirzepatide beyond weight loss.
Informed Peptide Editorial
The global peptide therapeutics market is expanding rapidly, driven by GLP-1 adoption, compounding pharmacy disruption, and growing consumer interest in longevity compounds. Here's what the data shows.
Informed Peptide Editorial
The FDA's evolving peptide compounding rules have created confusion for consumers and patients. This guide explains the key changes in 2025–2026 and what they mean for access to compounded peptides.
Informed Peptide Editorial
MOTS-c and KPV are among the most actively researched peptides in longevity and inflammation science. Here is what the current evidence shows — and what remains unknown.
Informed Peptide Editorial
With peptide use expanding rapidly, quality and safety concerns are real and underreported. This guide covers contamination risks, dosing variability, and how to evaluate whether a source is trustworthy.
Informed Peptide Editorial
A roundup of active and upcoming clinical trials for peptide-based therapeutics, from wound healing to metabolic disease to longevity applications.
ClinicalTrials.gov / Informed Peptide Editorial
No articles found in this category.
Peptide Research Agent
Ask anything about peptides
Research info only — not medical advice.
